Development of a Promising Ferritin-Based Bioconjugate Nanovaccine Candidate against Brucellosis
ACS Infectious Diseases · 14.11.2025 · 11 (11) · 3050-3060
DOI: 10.1021/acsinfecdis.5c00260 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 31.10.2025. Verfasst von Wenjun Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The Third Medical Centre of Chinese PLA General Hospital, The Training Site for Postgraduate of Jin Zhou Medical U…. Hauptthemen laut MEDLINE: Brucellosis, Ferritins, Brucella Vaccine, Nanoparticles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
Brucellosis, a global zoonosis caused by Brucella species, currently lacks safe vaccines for human use, while existing veterinary live-attenuated vaccines pose infection risks. Although ferritin nanoparticle materials have shown significant advantages in delivery, there is not much research on loading complex polysaccharide antigens. Here, we engineered a bioconjugate nanovaccine (Fn-OPS) through a bacterial glycosylation-driven synthetic strategy, which couples Yersinia enterocolitica O:9 (YeO9) O-specific polysaccharide (OPS)─a structural analogue of Brucella antigens─to a self-assembled ferritin nanoparticle (Fn). This nanocarrier platform combines the symmetrical architecture and antigen-presenting advantages of Fn with the precision of enzymatic glycosylation, addressing the limitations of complex chemical synthesis methods. After confirming the presence of monodisperse nanoparticles with stability at room temperature and great in vivo safety, we performed murine immunization studies and demonstrated a robust activation of T follicular helper (Tfh) cells and germinal center B cells, leading to the production of high-titer IgG antibodies that are cross-reactive with Brucella lipopolysaccharide. This immune response provides strong protection against Brucella infection. This work establishes a ferritin-based nanoconjugate platform for targeted delivery of complex polysaccharide antigens. It advances a scalable, biosafe strategy for Brucella vaccines, expanding the toolkit for targeted antigen delivery in conjugate vaccine design and broadening applications in infectious disease prophylaxis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, The Third Medical Centre of Chinese PLA General Hospital, The Training Site for Postgraduate of Jin Zhou Medical University, Beijing 100039, China.
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.
- The Third Medical Center, PLA General Hospital, Beijing 100039, China.
Förderung
- National Key Research and Development Program of China
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
- Beijing Nova Program
Zitieren
APA
Li, W., Li, J., Cao, X., Song, N., Li, T., Ye, J., Chen, Z., Lyu, Y., Zhu, L., Liu, Z., Yang, X., Wang, H., Pan, C., & Wang, Y. (2025). Development of a Promising Ferritin-Based Bioconjugate Nanovaccine Candidate against Brucellosis. ACS Infectious Diseases, 11(11), 3050-3060. https://doi.org/10.1021/acsinfecdis.5c00260
Vancouver
Li W, Li J, Cao X, Song N, Li T, Ye J, et al. Development of a Promising Ferritin-Based Bioconjugate Nanovaccine Candidate against Brucellosis. ACS Infectious Diseases. 2025;11(11):3050-3060. doi:10.1021/acsinfecdis.5c00260
BibTeX
@article{Li2025,
author = {Li, Wenjun and Li, Juntao and Cao, Xueping and Song, Na and Li, Ting and Ye, Jingqin and Chen, Ziyuan and Lyu, Yufei and Zhu, Li and Liu, Zhaoyang and Yang, Xiaoli and Wang, Hengliang and Pan, Chao and Wang, Yufei},
title = {Development of a Promising Ferritin-Based Bioconjugate Nanovaccine Candidate against Brucellosis},
journal = {ACS Infectious Diseases},
year = {2025},
volume = {11},
number = {11},
pages = {3050--3060},
doi = {10.1021/acsinfecdis.5c00260}
}
EUVIMED